Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03997760 · ClinicalTrials.gov registry record · Phase 1
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03997760 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 19 participants.
The verdict
NCT03997760, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants. Study participants will receive TAK-755 or placebo on Day 1. Their SCD will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be asked to follow-up on 13 days following SHP655 or placebo administration for safety assessment. Maximum duration of participation is expected to be about 2 months.
Interventions
- OTHER Placebo
- DRUG TAK-755
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2022-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03997760
The ClinicalTrials.gov registry entry for NCT03997760 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03997760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03997760 about?
NCT03997760 is a clinical study titled "A Study of SHP655 (rADAMTS13) in Sickle Cell Disease". TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants. Study participants will receive TAK-755 or placebo on Day 1. Their SCD will be treated by their doctor acco...
What is the current status of trial NCT03997760?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-10-21. Estimated completion is 2022-10-26.
What interventions are being tested in trial NCT03997760?
The interventions under investigation include: Placebo (OTHER), TAK-755 (DRUG).
Who is sponsoring clinical trial NCT03997760?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.